Neil Gordon

Neil is an Engineer/MBA business executive with over 30 years experience in the development and commercialization of cutting edge products and services. His education in metallurgical engineering included studies in electrochemistry. His early career was in engineering instrumentation and software.

Neil became one of the nanotechnology sector’s first business consultants and focused on the use of nanotechnology, biotechnology, and information technology breakthroughs for ultra-low levels of biological materials, He led initiatives for the Government of Taiwan’s national lab ITRI, the Canadian Government’s national lab NRC, and numerous companies and venture capitalists. He headed commercialization for the NASA-led CANEUS consortium for Micro and Nano Technologies in the Aerospace and Defense Industry where he interacted with NASA and DOD scientists in next generation nanotechnologies. Neil subsequently spun out a company from NASA’s Ames Research Center and transitioned NASA’s electrochemical carbon nanotube biosensor into an automated water sampling and detection instrument where he co-invented an instrument for remotely detecting water-borne pathogens. Under Neil’s leadership, the company raised $10 million in private and government funding and had a 35 person team of employees and contractors.

Neil subsequently founded Guanine Inc and invented the electrochemical oligonucleotide detection tag. In the performance of a CDC SBIR grant Neil’s team demonstrated the platform in a hybridization sandwich assay using 16S rRNA from lysed Klebsiella pneumoniae carbapenemase (KPC). KPC detection and antimicrobial susceptibility testing was achieved in under 1 hour using a hand-held potentiostat instead of 2 – 4 days employing isolation, culture and/or PCR. Neil patented an artificial intelligence platform that can diagnosis diseases and outbreaks from electrochemical detection signals associated with body and environmental samples, pattern recognition of rashes, and other inputs from patients, healthcare professionals and cloud-based databases. Guanine is partially owned by Mount Sinai Health System and is seeking venture capital to develop a syndromic POC test for sepsis infections and pursue licensing applications for its test kit.

Relevant Patents and Publications
1. Gordon, N. Bioanalyte signal amplification and detection with artificial intelligence diagnosis. United States Patent and Trademark Office, US 11,105,801 B2 (patent issued on August 31, 2022).

2. Gordon, N.. Ultra-sensitive bioanalyte quantification from self-assembled quadruplex tags. United States Patent & Trademark Office, US 11,175,285 B2 (patent issued on November 16, 2021).

3. Gordon, N. Ultra-sensitive detection of extremely low level biological analytes using electrochemical signal amplification and biosensor. United States Patent and Trademark Office, US 9,624,532 B2 (patent issued on April 18, 2017).

4. Gordon, N.; Bawa, R.; Palmateer, G. Detection of Pathogens and Antimicrobial Resistance Genes at Low Concentration via Electrochemical Oligonucleotide Tags. Eng. Proc. 2023, 35, 28. https://doi.org/10.3390/IECB2023-14584

5. Gordon, N.; Bawa, R.; Palmateer, G.; Rajabi, M.; Gordon, J.B.; Kotb, N.M.; Balasubramaniyam, R.; Gordon, B.R. Carbapenem-Resistant Enterobacteriaceae Testing in 45 Minutes Using Oligonucleotide Detection Tags. In Advances in Medical Imaging, Detection, and Diagnosis; Jenny Stanford Publishing Pte. Ltd.: 2023; Volume 4, pp. 813-828. ISBN 978-981-4877-46-6.

6. Jayamohan, H. Gale, B.K,. Minson, B.J., Lambert, C.J., Gordon, N., Sant, H.J. Highly sensitive bacteria quantification using immunomagnetic separation and electrochemical detection of guanine-labeled secondary beads. Sensors, 15, 12034–12052.